SBRT for early stage lung cancer: outcomes from biopsy-proven and empirically treated lesions-Reference-Cited by-同舟云学术

SBRT for early stage lung cancer: outcomes from biopsy-proven and empirically treated lesions

Published:2018-03-01 Issue:1 Volume:7 Page:LMT01
ISSN:1758-1966
Container-title:Lung Cancer Management
language:en
Short-container-title:Lung Cancer Management

Author:

Wegner Rodney E¹,Ahmed Nissar¹,Hasan Shaakir¹,Schumacher Lana Y²,Van Deusen Matthew²,Colonias Athanasios¹

Affiliation:

1. Allegheny Health Network, Cancer Institute, Division of Radiation Oncology, Pittsburgh, PA 15212, USA

2. Allegheny Health Network, Department of Thoracic Surgery, Pittsburgh, PA 15212, USA

Abstract

Aim: Herein, we compare outcomes in patients treated with lung stereotactic body radiotherapy (SBRT) with and without tissue confirmation. Methods: We reviewed 196 patients that underwent lung SBRT for presumed (100 patients) or proven non-small-cell lung cancer (96 patients) over a 10-year period and compared outcomes. Results: A total of 196 patients with a median age of 76 underwent lung SBRT to a median dose of 48 Gy in four fractions. Median follow up was 17 months. Local control and overall survival at 3 years was 94 and 58% for the entire group. There was no difference in overall survival, local control, regional control or distant control between the cohorts. Conclusion: SBRT is a safe and effective treatment for patients with non-small-cell lung cancer that are medically inoperable with comparable results in empirically treated patients.

Publisher

Future Medicine Ltd

Subject

Pulmonary and Respiratory Medicine,Oncology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/lmt-2018-0006

Reference14 articles.

1. The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours

2. Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy

3. Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer

4. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation

5. Increase in the use of lung stereotactic body radiotherapy without a preceding biopsy in the United States

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Histology-driven hypofractionated radiation therapy schemes for early-stage lung adenocarcinoma and squamous cell carcinoma;Radiotherapy and Oncology;2024-06

2. Pathologic Nodal Staging Before SBRT for Early-stage NSCLC Does Not Impact Overall Survival;American Journal of Clinical Oncology;2023-09-08

3. Optimal Radiation Therapy Fractionation Regimens for Early-Stage Non-Small Cell Lung Cancer;International Journal of Radiation Oncology*Biology*Physics;2023-09

4. Local control and survival after stereotactic body radiation therapy of early-stage lung cancer patients in Slovenia;Radiology and Oncology;2023-07-26

5. Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional Model;Journal of Thoracic Oncology;2023-03